[A23-110 ] Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2024
Project no.:
A23-110
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FMS-like tyrosine kinase 3 mutation-positive
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-110_en
| Project no. | Title | Status |
|---|---|---|
| A23-111 | Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-34 | Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110 | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.